Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 15974926

Drug library screen to identify compounds that decrease secreted Abeta from a human cell line.

Enakshi Chakrabarti·Jonathan D Smith
View original source ↗Export metadata ↓

Abstract

In order to discover compounds that may be useful in the prevention of Alzheimer disease, a drug library was screened for drugs that could decrease amyloid beta peptide (Abeta) accumulation secreted from a human CNS-derived cell line. Of the 2160 compounds subjected to a primary screen, 16, or 0.74%, reduced Abeta accumulation by at least 40%. Seven of these compounds were confirmed to be effective in a secondary screen using each compound at a dose of 5 microM. Three of these seven compounds were more effective than the others at reducing Abeta levels in a tertiary screen, and led to 68 to 85% reductions in total Abeta, at the 25 microM dosage. The effects of these three drugs on secreted Abeta40, Abeta42, and sAPPalpha were also determined. Thus, we have identified lead compounds that may be useful for subsequent studies to determine the mechanism of action of each drug, as well as for pre-clinical studies to determine whether each of these drugs is safe and effective in vivo.

Explore related subjects

Amyloid beta-PeptidesCell LineDose-Response Relationship, DrugDrug Evaluation, PreclinicalHumansNeuroprotective AgentsComparative StudyJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Enakshi Chakrabarti, Jonathan D Smith. 2005. Drug library screen to identify compounds that decrease secreted Abeta from a human cell line.. https://doi.org/10.2174/1567205053585738

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2026

Subcellular proteomic analysis of the DDR2 interactome in a neuronal cell model exposed to Aβ42.

Receptor tyrosine kinases (RTKs) are increasingly understood to signal beyond the plasma membrane. However, the role of Discoidin domain receptor 2 (DDR2), which is activated by collagen, in neurodegeneration remains poorly understood. This study uses immunoprecipitation followed by mass spectrometry on cytoplasmic and nuclear fractions from a neuronal cell model to show that Aβ42 exposure is associated with a compartment-specific reorganization of DDR2-associated protein complexes, characterized by increased nuclear representation. This reveals a unique nuclear DDR2 interactome under amyloidogenic conditions. By exploring this non-canonical, compartment-specific DDR2 signaling pathway, our results offer new insights into how receptor signaling networks may be altered in Alzheimer's disease pathology. Additionally, we identify DDR2-related nuclear interactions as potential sites of dysregulation in neurodegeneration.

Amyloid beta-Peptides↗
PubMed2006

Amyloid beta oligomerization is induced by brain lipid rafts.

Detergent-resistant lipid rafts are required for the generation of Abeta as they concentrate not only amyloid precursor protein (APP), but also the beta- and gamma-secretase that convert APP to Abeta. Recently, Abeta has been shown to be oligomerized, which results in neuronal cytotoxicity and synaptic failure. In this study, we have demonstrated that Abeta oligomers appeared immediately after the incubation of Abeta with lipid rafts isolated from the brain tissues of rats, and were converted into few Abeta fibrils, even after longer periods of incubation. The oligomerization of Abeta was not abolished after the brain lipid rafts were treated with heat, or with protease K, implying that the lipid raft proteins were determined not to be prerequisites for Abeta oligomerization. The cholesterol present in the lipid rafts might not be essential to Abeta oligomerization because Abeta oligomerization was not prevented after the cholesterol was removed from the lipid rafts with methyl-beta-cyclodextrin (MbetaCD). The Abeta oligomerization was accelerated by the application of lipid rafts isolated from ganglioside-rich cells, C2C12 cells, whereas this was not observed with the lipid rafts isolated from ganglioside-poor cells SK-N-MC and HeLa cells. In addition, lipid raft-induced Abeta oligomerization was shown to be inhibited in CHO-K1 cells which were defective with regard to ganglioside biosynthesis. This indicates that Abeta oligomerization requires gangliosides that are enriched in the lipid rafts.

Amyloid beta-Peptides↗
PubMed2006

In vivo protective effects of ferulic acid ethyl ester against amyloid-beta peptide 1-42-induced oxidative stress.

Alzheimer's disease (AD) is a neurodegenerative disorder characterized by the deposition of amyloid-beta peptide (Abeta), a peptide that as both oligomers and fibrils is believed to play a central role in the development and progress of AD by inducing oxidative stress in brain. Therefore, treatment with antioxidants might, in principle, prevent propagation of tissue damage and neurological dysfunction. The aim of the present study was to investigate the in vivo protective effect of the antioxidant compound ferulic acid ethyl ester (FAEE) against Abeta-induced oxidative damage on isolated synaptosomes. Gerbils were injected intraperitoneally (i.p.) with FAEE or with dimethylsulfoxide, and synaptosomes were isolated from the brain. Synaptosomes isolated from FAEE-injected gerbils and then treated ex vivo with Abeta(1-42) showed a significant decrease in oxidative stress parameters: reactive oxygen species levels, protein oxidation (protein carbonyl and 3-nitrotyrosine levels), and lipid peroxidation (4-hydroxy-2-nonenal levels). Consistent with these results, both FAEE and Abeta(1-42) increased levels of antioxidant defense systems, evidenced by increased levels of heme oxygenase 1 and heat shock protein 72. FAEE led to decreased levels of inducible nitric oxide synthase. These results are discussed with potential therapeutic implications of FAEE, a brain accessible, multifunctional antioxidant compound, for AD involving modulation of free radicals generated by Abeta.

Amyloid beta-Peptides↗